Skip to content
Recovery & Performance PeptidesRecovery research and practical context
Recovery article

Thymosin Beta-4 Dosing: 750mcg Loading Protocol (2026)

Affiliate disclosure: vendor links in this article are affiliate links — The Peptide Catalog may earn a commission if you buy through them, at no additional cost to you. Ready to buy? Compare verified vendors on our best thymosin beta-4 sources page, or browse

Affiliate disclosure: vendor links in this article are affiliate links — The Peptide Catalog may earn a commission if you buy through them, at no additional cost to you.

Ready to buy? Compare verified vendors on our best thymosin beta-4 sources page, or browse all coupon codes for up to 50% off.

Where These Numbers Come From

Community TB-4 doses are conservatively extrapolated from a large body of animal research, with some reference to human safety data.

Animal Study Doses: Nearly all TB-4 research uses 6 mcg/mouse IP (~0.24 mg/kg). Using standard allometric scaling to a 70 kg human gives a human equivalent of ~17 mg single dose, or ~5-10 mg/week. Community doses (5-10 mg/week loading, 2-5 mg/week maintenance) sit in the conservative middle of this range.

Phase I Human Safety (Ruff et al., 2010): Massive IV doses of 42, 140, 420, and 1,260 mg were well-tolerated in healthy subjects — no dose-limiting toxicity. This was safety testing, not therapeutic dosing.

Key mechanisms: Actin sequestration for cell migration (Mannherz & Huff, 2011), VEGF-driven angiogenesis (Philp et al., 2003), NF-kB suppression for anti-inflammatory effects (Sosne et al., 2007), and Akt survival signaling (Bock-Marquette et al., 2004).

Stacking Protocols

TB-4 + BPC-157 (Popular Healing Stack)

TB-4

750 mcg daily (loading) / 500 mcg 2x/week (maintenance)

SC

AM

Actin remodeling, cell migration, anti-inflammatory

BPC-157

250-500 mcg daily

SC (near injury)

Angiogenesis, growth factors, GI protection

TB-4 + GHK-Cu

Per protocol

Cell migration, tissue repair

GHK-Cu

1-3 mg 2x/week

Collagen synthesis, wound remodeling

TB-4 vs TB-500

Structure

Full 43-amino-acid peptide

Synthetic 17-23 AA fragment

Weekly dose

5-10 mg (loading)

3.5 mg (500 mcg daily)

Contains LKKTET

Yes (angiogenesis domain)

No

Primary use

Broad tissue repair + angiogenesis

Focused actin migration

For the complete comparison, see TB-4 vs TB-500.

Side Effects & Safety

Injection site irritation — mild, transient

Rare mild fatigue — occasional community report

No hormonal disruption — unlike some peptides

Phase I human safety — IV doses up to 1,260 mg well-tolerated with no serious adverse events

No mutagenic or carcinogenic effects in long-term animal studies

Theoretical angiogenic concern — pro-angiogenic effects raise questions about existing tumors, though no evidence of tumor promotion exists

No long-term human data at community doses

mg to Units Conversion

On a standard 100-unit insulin syringe, each "unit" equals 0.01 mL (so 100 units = 1 mL). Once thymosin beta-4 is reconstituted, the conversion from a target dose to syringe units depends on the chosen dilution.

The two reconstitution ratios most often described in community protocols are below.

Reconstitution A: 10 mg vial + 2 mL BAC water (5 mg/mL) — the standard dilution from the Quick Reference above.

400 mcg

0.08 mL

8 units

750 mcg

0.15 mL

15 units

1100 mcg

0.22 mL

22 units

1500 mcg

0.3 mL

30 units

Reconstitution B: 10 mg vial + 3 mL BAC water (3.33 mg/mL) — more BAC water for larger, easier-to-measure draws.

0.12 mL

12 units

0.225 mL

22.5 units

0.33 mL

33 units

0.45 mL

45 units

These conversions reflect the dilutions documented in community reconstitution protocols. They report how the math is described, not a recommended dosing schedule.

Core Supplies for This Protocol

The three essentials for running any reconstituted injectable: cold storage, accurate syringes, and metabolic tracking.

Cooluli Classic 4L Mini Fridge

Compact thermoelectric mini-fridge with heat/cool toggle. The most-mentioned dedicated peptide-storage fridge in research community sources — fits ~20 vials and runs quietly.

BD Ultra-Fine 31G 0.3cc 5/16" Insulin Syringes (Box of 90)

0.3cc 31G syringes — each gradation marks 1 unit (vs 2 units on 1cc), making sub-50-unit peptide doses accurate. BD Ultra-Fine is the most widely-cited brand in peptide community sources.

CONTOUR NEXT GEN Glucose Meter All-In-One Kit

Ascensia's CONTOUR NEXT GEN — the most clinically-validated home glucose meter. Includes 20 test strips + lancing device. Tracks the blood-sugar response GLP-1 users care about, especially during dose escalation.

As an Amazon Associate, The Peptide Catalog earns from qualifying purchases.

CONNECTED / MODULES

Post-session references

Selected from shared article topics. Source links are retained where available.

01

Handling & safety lane

Source-derived education, not individual medical guidance or an instruction to dose.

DOSAGE SOURCE

Quick Dosing Reference · research convention, not a validated dose

4 100 0.1mg 10 250 0.25mg 20 500 0.5mg 750 0.75mg 40 1000 1mg
03

Evidence cooldown

Research context and source excerpts for a slower second read.

RESEARCH

Cardiomyocyte Protection Research: Ischaemia-Reperfusion and Apoptosis

Cardiac ischaemia-reperfusion (I/R) injury is the primary research context for Tβ4 cardiomyocyte protection. Primary neonatal rat ventricular myocytes (NRVM, P1-P3 rat hearts, collagenase II type II enzymatic dissociation, Percoll 40.5/58.5% gradient purification, plated 4×10⁵/cm² in 10% FBS DMEM/M199 4:1, beating monolayer confirmation at 48-72h) subjected to simulated ischaemia (SI/R: hypoxia 94%N₂/5%CO₂/1%O₂, glucose-free PBS, 60-90 min) → reoxygenation (normoxic complete medium, 120 min) with Tβ4 pre-treatment (10-1000 ng/mL, 24h before SI) or post-treatment (at reperfusion onset). Cardiomyocyte viability endpoints: LDH release (Promega CytoTox 96, OD490, % cytotoxicity); propidium iodide (PI) inclusion flow cytometry; ATP content (CellTiter-Glo, Promega, relative luminescence); JC-1 mitochondrial membrane potential (ΔΨm, 530 nm green monomer vs 590 nm red aggregate, depolarisation indicating apoptosis onset). Apoptosis endpoint cascade: cytochrome c (cytosolic ELISA or western), caspase-9 and caspase-3 activity (Caspase-Glo substrates), PARP cleavage western, and TUNEL (in situ cell death detection, Roche, fixed sections). Akt Ser-473 and ERK1/2 Thr-202/Tyr-204 phosphorylation western (Tβ4-ILK-PI3K-Akt and Tβ4-Akt-ERK MAPK survival cascades) with PI3K inhibitor LY294002 (10 μM) and MEK inhibitor PD98059 (10 μM) separating PI3K-Akt versus MAPK-ERK contributions to Tβ4 protection. In vivo MI model: C57BL/6 mouse left anterior descending (LAD) coronary artery ligation (permanent or 30-min occlusion-reperfusion), Tβ4 treatment by pericardial injection (1.6 mg/kg at time of surgery), i.p. injection (20-100 μg/mouse), or pre-treated slow-release subcutaneous pellet. Echocardiography (Vevo 2100 or 3100, 30 MHz transducer, M-mode and B-mode): LVEF (Simpson’s biplane method), FS (fractional shortening), LVEDD, LVESD, LV mass (Devereux formula) at baseline, 24h, 7d, 28d post-MI. TTC infarct sizing at 24h (% LV); cardiac troponin I (cTnI) plasma ELISA; histology: Masson trichrome (scar area % LV), α-SMA+ myofibroblast density (scar border zone), and CD31 neovessel density (border zone, vessels/mm²) at 7d and 28d.

RESEARCH

Thymosin Beta 4 (TB-500) and Related Research Studies

by Dr. Usman | Mar 30, 2022 | Research Thymosin Beta-4 has been documented by researchers to potentially play a role in protecting, regenerating, and remodeling damaged tissue cells. After any tissue injury, it is believed that Thymosin Beta-4 may be released by damaged cells to protect them and reduce the inflammatory process. This peptide is believed to be present in every tissue except red cells. Studies suggest that the first gene coding to occur (the process by which DNA and RNA dictate how and which cells need to form) after cell damage is Thymosin Beta-4. The formation of new blood vessels is believed to be essential to promote tissue repair. Damaged cells are believed to require early nutrients and supportive chemicals to reverse the damage. Thymosin Beta-4 is believed to have an angiogenic quality speculated to stimulate the migration and proliferation of endothelial cells.

POTENTIAL BENEFITS

Anti-Aging Benefits

TB-4’s regenerative properties extend to skin health as well. It can help reduce the appearance of fine lines and wrinkles, improve skin elasticity, and promote a youthful complexion.
05

Product & matchup locker

Linked catalog and comparison files.

Comparison

4. Thymosin Beta-4 vs TB-500

This is one of the most common questions in peptide research. TB-500 is not the same peptide as Thymosin Beta-4, though they are closely related.